INVESTOR NOTICE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab during clinical trials [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc. and covers purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1]. - Investors have until April 6, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on Osteogenesis Imperfecta patients and downplayed the risks associated with the Phase III Orbit study [3]. Group 2: Study Results and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - On December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx stock during the class period to seek lead plaintiff status, representing the interests of the class [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].